OPTIMIZING THE DAILY UNITS OF INSULIN; INSULIN DEGLUDEC ASPART VERSUS PREMIXED INSULIN ASPART IN THE STANDARD OF CARE REGIMEN FOR TYPE 2 DIABETICS
Keywords:Biphasic Insulin Aspart, Glycemic Control, Insulin Degludec Aspart, Type 2 Diabetes Mellitus
AbstractB Background: This study aimed to evaluate the impact of Insulin Degludec Aspart on daily insulin dose in comparison with premixed insulin aspart. Methods: It was a Quasi-Experimental study conducted in the Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi and the Department of Medicine, Pak Emirates Military Hospital, Rawalpindi. One hundred and twenty participants with documented type 2 diabetes, taking premixed insulin aspart therapy were enrolled in the study. Sixty participants were substituted with insulin degludec aspart from premixed insulin aspart. Daily units of insulin were recorded for 12 weeks and compared for both groups. SPSS version 26 was used for analysing the study results. Results: Participants of the insulin degludec aspart group showed a significant reduction in the daily insulin dose compared to the premixed insulin aspart group. Fifty-two units per day were administered in the participants of the premixed insulin aspart patients while insulin degludec aspart participants received 40 units of median daily insulin dose (p-value<0.001). Conclusion: Insulin degludec aspart proved superior to premixed insulin aspart in a reduction in the daily dose of insulin with insulin degludec aspart
Evert AB, Dennison M, Gardner CD, Garvey WT, Lau KHK, MacLeod J, et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. Diabetes Care 2019;42(5):731–54.
Almetwazi M, Alwhaibi M, Balkhi B, Almohaini H, Alturki H, Alhawassi T, et al. Factors associated with glycaemic control in type 2 diabetic patients in Saudi Arabia. Saudi Pharm J 2019;27(3):384–8.
Yu B, Lin F, Wang M, Ning H, Ling B, Rao Y. Efficacy and safety of dulaglutide compared with the first-line hypoglycaemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 2022;12(1):18281.
LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab 2019;104(5):1520–74.
Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G. Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials. BMJ Open Diabetes Res Care 2020;8(1):001477.
Glastras SJ, Cohen N, Dover T, Kilov G, MacIsaac RJ, McGill M, et al. The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia. J. Clin. Med 2020; 9(4): 1091.
Mehta R, Chen R, Hirose T, John M, Kok A, Lehmann R, et al. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. Diabetes Obes Metab 2020;22(11):1961–75.
Sendekie AK, Netere AK, Belachew EA. Hypoglycaemic events and glycaemic control effects between NPH and premixed insulin in patients with type 2 diabetes mellitus: A real-world experience at a comprehensive specialized hospital in Ethiopia. PLoS One 2022;17(9):e0275032.
Owens DR, Traylor L, Mullins P, Landgraf W. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract 2017;124:57–65.
Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011;13(8):677–84.
Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, et al. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial. Diabetes Obes Metab 2019; 21(7):1652–1660.
Hirose T, Awata T, Yamamoto Y, Hemmingsen MP. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients. Expert Opin Biol Ther 2018;18(1):77–85.
Cho KY, Nakamura A, Oba-Yamamoto C, Tsuchida K, Yanagiya S, Manda N, et al. Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial. Diabetes Metab J 2020;44(4):532–41.
Lane WS, Favaro E, Rathor N, Jang HC, Kjærsgaard MIS, Oviedo A, et al. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or WithoutMetformin, in Adults With Type 2 Diabetes (ONSET 9). Diabetes Care 2020;43(8):1710–6.
Ryzodeg PI. Prescribing Information. [Internet]. [cited 2019 Dec 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203313s002lbl.pdf
Demir T, Turan S, Unluhizarci K, Topaloglu O, Tukek T, Gogas Yavuz D. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns. Front Endocrinol (Lausanne) 2021;12:616514.
Heise T, Korsatko S, Nosek L, Coester HV, Deller S, Roepstorff C, et al. Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action. J Diabetes 2016;8(1):132–8.
Haahr H, Fita EG, Heise T. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Clin Pharmacokinet 2017;56(4):339–54.
Liebl A, Mohan V, Yang W, Strojek K, Linjawi S. 15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes. Drugs R D 2018;18(1):27–39.
Fujimoto K, Iwakura T, Aburaya M, Matsuoka N. Twice-daily insulin degludec/insulin aspart effectively improved morning and evening glucose levels and quality of life in patients previously treated with premixed insulin: an observational study. Diabetol Metab Syndr 2018;10:64.
Copyright (c) 2023 Komal Mumtaz Malik, Kulsoom Farhat, Shabana Ali, Mudassar Noor, Bilal Ahmad
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.